Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 669
Non-Exclusive Product/Services Biopsy needles, including aspiration, cutting needles and breast localization needles; Interventional guidewires (for use in all applications); Interventional vascular catheters (<6 hours), including PTCA, predilation, etc.; Indwelling vascular catheters (>6 hours), including CVC, PICC, etc.; Pacemakers, including leads; Implantable cardiac defibrillators and related devices, including their leads; Auditory implants, e.g. cochlear implants; Neuro stimulation including deep brain.
IPSCIO Record ID: 209508
At Licensees option, a non-exclusive, worldwide license to import, export, use, sell, and offer for sale Licensee Stent Systems incorporating or utilizing Licensors Lubricious Coating.
The Covered Products means either or both Coated Stents and Licensee Stent Systems incorporating or utilizing Licensors Lubricious Coating.
The patents relate to Endovascular Stents and coatings.
Biolimus A9 is formulated to inhibit excessive tissue formation around the stent following implantation, a common side effect called restenosis which often threatens to reverse the clinical benefits of the angioplasty and stent implantation procedures.
In Japan, Licensees Licensed Field of Use is further limited to treating long lesions, multiple vessels or small vessels in coronary and peripheral applications.
IPSCIO Record ID: 26702
Excluded License field shall mean MRI-guided temporary catheters that do not provide a pacemaker function.
IPSCIO Record ID: 299236
This agreement is extending Licenseeâ€™s worldwide right and license to use, manufacture, have manufactured, distribute and sell, and to grant sublicenses to its Affiliates to use, manufacture, have manufactured, distribute and sell, the Licensor Technology in the Peripheral Vascular Field of Use and the GI Field of Use.
Licensor newly grants its licensee, the right for Licensee to have third party Distributors distribute Eligible Peripheral Vascular and/or GI Products.
This agreement is co-exclusive with an option to become exclusive.
The license agreement regards paclitaxel-eluting stent products and related technologies. Paclitaxel is released from the balloon or stent to prevent scar tissue formation in the blood vessel that can re-obstruct the artery (restenosis).
As used herein, the Peripheral Vascular Field of Use means the endoluminal vascular licensed applications for the treatment or preventionof disease of the peripheral blood vessels of the body. Notwithstanding the foregoing, Peripheral Vascular Field of Use excludes any application in the Coronary Vascular Field of Use.
GI Field of Use means the endoluminal licensed applications for the treatment or prevention of disease of the alimentary tract or liver.
IPSCIO Record ID: 372411
Product shall mean and comprise a combination of hardware, software and workflow procedures allowing the performance of the Application or parts thereof under simultaneous MR imaging, which the Parties wish to develop under this Agreement and which is defined in more detail in Agreement. The Product shall be integrated and developed by Licensor as a medical product according to applicable local medical product regulations including, but not limited to the EU and the USA, integrating and combining the Software, MR System, Catheter Technology and Peripheral Technology. The summary describes the components and operation of an MRI-guided EP ablation system. The system uses active (signal receiving) invasive devices and special software for customized image reconstruction and display. In the prototyping phase, the software component of the system will run on a computer attached to the scanner, while for the product version, the software component of the system will run on the scanners host computer.
MR System shall mean any applicable Licensee MR system. Target MR System for the Product include the Magnetom Verio and the Magnetom Espree. Other MR System might be added after mutual agreement. The MR System is currently provided by Licensee as a medical product according to applicable local medical product regulations in several countries, including, but not limited to, the EU, Canada and the USA.
Software means software and dedicated MR sequences, which are developed by Licensee according to requirement specifications by Licensor. These specifications are defined in the Agreement. For the avoidance of doubt, Software does not include the base modules IFE and IRTTT, or any further developments or future versions of IFE or IRTTT, but only the dedicated plug in module dedicated to the workflow of the Product developed under this Agreement.
Background Patents shall mean patent applications, patents, utility models and other statutory protection with regard to MR System, Application, Catheter Technology, Peripheral Technology, Software, Integration or the Product under which one PARTY is the owner and/or has the right of determination at any time during the term of this Agreement and which are not a Development Result.
Catheter Technology shall mean and comprise the invasive medical devices (e.g. guidewire, catheters) supplied by Licensor for the use in the Product and within and in close proximity to an MR System and which are defined in this Agreement. The Catheter Technology shall be provided by Licensor as a medical product according to applicable local medical product regulations including, but not limited to, the EU and the USA.
Peripheral Technology means hardware and software required by the user to perform the Application with the Product and which is not already included in Catheter Technology or Software or MR System.
Application shall mean the treatment of cardiac arrhythmia by catheter mediated ablation under simultaneous MR imaging and catheter mediated cardiac electrophysiological mapping under simultaneous MR imaging by using the Product. In the event the width of an Application is specified through guidelines of regulatory bodies like SFDA, CE, FDA, such specification shall apply.
The Parties wish to establish a Cooperation and Development Agreement aiming at a combination of the capabilities of Catheter Ablation and MR imaging in developing a product combination that allows performing the treatment of cardiac arrhythmias by catheter mediated ablation and catheter mediated cardiac electrophysiological mapping procedure under simultaneous MR imaging for worldwide marketing and sales. The Parties agree that this treatment consists of a procedure with the involvement of different medical devices, including catheters and mapping technology as well as MR imaging guidance. The Parties intend to develop an MR workflow with all required components integrated into the special requirements of the MR environment.
Field shall mean treatment of cardiac arrhythmia by catheter mediated ablation under simultaneous MR imaging and catheter mediated cardiac electrophysiological mapping under simultaneous MR imaging.
IPSCIO Record ID: 5753
The parties agree that upon completion of the research and development contemplated by this Agreement, they will negotiate and enter into an agreement pursuant to which the Licensee will have the exclusive right to manufacture and sell the Stents.
IPSCIO Record ID: 117
IPSCIO Record ID: 289542
6,970,742 – Method for detecting, diagnosing, and treating cardiovascular disease
6,328,699 – Permanently implantable system and method for detecting, diagnosing and treating congestive heart failure
IPSCIO Record ID: 28166
The Licensed Technology means the ColorMark(R) technology, and shall include all Licensor's U.S. and foreign patents and patent applications, currently existing or existing in the future, related thereto.
IPSCIO Record ID: 222533
Medical Products means the vessel connector and flow-limiter components of a surgically implanted graft prosthetic system for coupling vascular members in the coronary asculature, such as the vessel connector and flow-limiter components of the devices in the illustrations in U.S. Patent 6,241,764 B1.
6,241,764 – Stented grafts for coupling vascular members
Drug-Delivery Coating means chemical compositions comprised of poly(ethylene-co-vinyl acetate) and poly(butyl methacrylate) components for the purpose of releasing Compounds from the chemical composition.
Hemocompatable Coating means chemical coating compositions that contain one or more of the following components photo-reactive polyvinylpyrrolidone copolymer, nonphoto-reactive polyvinylpyrrolidone, photo-reactive heparin, a crosslinking agent known to the parties as PR04, and a compound for promoting polymer-to-metal adhesion and known to the parties as TL03, for the purpose of providing a hemocompatable surface to the Medical Products.
Licensor U.S. Patents
Hemocompatable Coating formulations
METHOD OF IMPROVING THE BIOCOMPATIBILITY OF SOLID SURFACES
U.S. Patent No. 4,973,493 issued 11/27/1990
BIOCOMPATIBLE COATINGS FOR SOLID SURFACES
U.S. Patent No. 4,979,959 issued 12/25/1990
PREPARATION OF POLYMERIC SURFACES VIA COVALENTLY ATTACHING POLYMERS
U.S. Patent No. 5,002,582 issued 3/26/1991
BIOCOMPATIBLE DEVICE WITH COVALENTLY BONDED BIOCOMPATIBLE AGENT
U.S. Patent No. 5,263,992 issued 11/23/1993
SUBSTRATE SURFACE PREPARATION
U.S. Patent No. 5,512,329 issued 4/30/1996
PHOTOACTIVATABLE CROSS-LINKING AGENTS CONTAINING CHARGED GROUPS FOR WATER SOLUBILITY
U.S. Patent No. 6,077,698 issued 06/20/2000
SURFACE COATING AGENTS
U.S. Patent No. 6,278,018 B1 issued 08/21/2001
SURFACE COATING AGENT
U.S. Patent No. 6,603,040B1 issued 8/05/2003
SILANE COATING COMPOSITION
U.S. Patent No. 6,706,408B2 issued 3/16/2004
Drug-Delivery Coating formulations
BIOACTIVE AGENT RELEASE COATING
U.S. Patent No. 6,214,901B1 issued 04/10/2001
BIOACTIVE AGENT RELEASE COATING
U.S. Patent No. 6,344,035B1 issued 02/05/2002
IPSCIO Record ID: 26532
IPSCIO Record ID: 163887